Unlocking the potential of immune checkpoint inhibitors in the papillary renal cell carcinoma setting

Unity Health Toronto received a $879,847 Project Grant award from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420), effective August 1, 2025, through July 31, 2029. The research initiative, titled "Unlocking the Potential of Immune Checkpoint Inhibitors in the Papillary Renal Cell Carcinoma Setting," will be conducted at the organization's facility located in Ottawa, Ontario, Canada. The awardee will deliver hypothesis-driven research and development services focused on investigating immunotherapy approaches for treating papillary renal cell carcinoma, contributing to the DHA's mission to transform healthcare for both military service members and the broader American public through innovative medical solutions.

Under the Military Medical Research and Development program, award recipients are expected to deliver research and development services, including biomarker discovery, therapeutic development, and translational research activities. The four-year performance period aligns with typical timelines for this assistance listing, which generally supports basic, applied, and advanced biomedical research initiatives addressing critical health challenges. The award reflects the program's emphasis on cancer immunotherapy research and represents competitive selection through a two-tier review process evaluating technical merit and military relevance.